Display options
Cite
McKay J, Tenet V, Franceschi S, et al. Immuno-related polymorphisms and cervical cancer risk: The IARC multicentric case-control study. PLoS One. 2017;12(5):e0177775doi: 10.1371/journal.pone.0177775.
McKay, J., Tenet, V., Franceschi, S., Chabrier, A., Gheit, T., Gaborieau, V., Chopin, S., Avogbe, P. H., Tommasino, M., Ainouze, M., Hasan, U., & Vaccarella, S. (2017). Immuno-related polymorphisms and cervical cancer risk: The IARC multicentric case-control study. PloS one, 12(5), e0177775. https://doi.org/10.1371/journal.pone.0177775
McKay, James, et al. "Immuno-related polymorphisms and cervical cancer risk: The IARC multicentric case-control study." PloS one vol. 12,5 (2017): e0177775. doi: https://doi.org/10.1371/journal.pone.0177775
McKay J, Tenet V, Franceschi S, Chabrier A, Gheit T, Gaborieau V, Chopin S, Avogbe PH, Tommasino M, Ainouze M, Hasan U, Vaccarella S. Immuno-related polymorphisms and cervical cancer risk: The IARC multicentric case-control study. PLoS One. 2017 May 15;12(5):e0177775. doi: 10.1371/journal.pone.0177775. eCollection 2017. PMID: 28505207; PMCID: PMC5432183.
Copy Download .nbib Format: NLM
Share it on

PLoS One. 2017 May 15;12(5):e0177775. doi: 10.1371/journal.pone.0177775. eCollection 2017.

Immuno-related polymorphisms and cervical cancer risk: The IARC multicentric case-control study.

PloS one

James McKay, Vanessa Tenet, Silvia Franceschi, Amélie Chabrier, Tarik Gheit, Valérie Gaborieau, Sandrine Chopin, Patrice H Avogbe, Massimo Tommasino, Michelle Ainouze, Uzma Hasan, Salvatore Vaccarella

Affiliations

  1. International Agency for Research on Cancer, Lyon, France.
  2. Centre International de Recherche en Infectiologie, International Center for Infectiology Research (CIRI), Lyon, France.
  3. Inserm, U1111, Lyon, France.
  4. Ecole Normale Supérieure de Lyon, Lyon, France.
  5. University Lyon 1, Lyon, France.
  6. CNRS, UMR5308, Lyon, France.
  7. Laboratoire d'Immunologie, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Lyon, France.

PMID: 28505207 PMCID: PMC5432183 DOI: 10.1371/journal.pone.0177775

Abstract

A small proportion of women who are exposed to infection with human-papillomavirus (HPV) develop cervical cancer (CC). Genetic factors may affect the risk of progression from HPV infection to cervical precancer and cancer. We used samples from the International Agency for Research on Cancer (IARC) multicentric case-control study to evaluate the association of selected genetic variants with CC. Overall, 790 CC cases and 717 controls from Algeria, Morocco, India and Thailand were included. Cervical exfoliated cells were obtained from control women and cervical exfoliated cells or biopsy specimens from cases. HPV-positivity was determined using a general primer GP5+/6+ mediated PCR. Unconditional logistic regression was used to estimate odds ratios (OR) and corresponding 95% confidence intervals (CI) of host genotypes with CC risk, using the homozygous wild type genotype as the referent category and adjusting by age and study centre. The association of polymorphisms with the risk of high-risk HPV-positivity among controls was also evaluated. A statistically significant association was observed between single nucleotide polymorphism (SNP) CHR6 rs2844511 and CC risk: the OR for carriers of the GA or GG genotypes was 0.70 (95% CI: 0.43-1.14) and 0.61 (95% CI: 0.38-0.98), respectively, relative to carriers of AA genotype (p-value for trend 0.03). We also observed associations of borderline significance with the TIPARP rs2665390 polymorphism, which was previously found to be associated with ovarian and breast cancer, and with the EXOC1 rs13117307 polymorphism, which has been linked to cervical cancer in a large study in a Chinese population. We confirmed the association between CC and the rs2844511 polymorphism previously identified in a GWAS study in a Swedish population. The major histocompatibility region of chromosome 6, or perhaps other SNPs in linkage disequilibrium, may be involved in CC onset.

References

  1. Oncoimmunology. 2014 Jan 1;3(1):e27257 - PubMed
  2. Int J Cancer. 2003 Oct 20;107(1):127-33 - PubMed
  3. J Exp Med. 2013 Jul 1;210(7):1369-87 - PubMed
  4. PLoS Genet. 2013;9(3):e1003212 - PubMed
  5. J Clin Microbiol. 2002 Mar;40(3):779-87 - PubMed
  6. PLoS One. 2012;7(4):e33619 - PubMed
  7. Int J Cancer. 2000 Jul 15;87(2):221-7 - PubMed
  8. Lancet. 2007 Nov 10;370(9599):1609-21 - PubMed
  9. J Clin Microbiol. 1995 Apr;33(4):901-5 - PubMed
  10. Lancet. 2007 Sep 8;370(9590):890-907 - PubMed
  11. Int J Cancer. 2005 Jan 20;113(3):483-9 - PubMed
  12. Int J Cancer. 2006 Sep 1;119(5):1108-24 - PubMed
  13. Lancet Oncol. 2016 Oct;17 (10 ):1445-1452 - PubMed
  14. J Natl Cancer Inst. 1998 Jan 7;90(1):50-7 - PubMed
  15. J Natl Cancer Inst. 2013 May 1;105(9):624-33 - PubMed
  16. BMC Cancer. 2013 Jan 15;13:19 - PubMed
  17. Eur J Cancer. 2013 Oct;49(15):3262-73 - PubMed
  18. Cancer Immunol Immunother. 2010 Jul;59(7):1021-8 - PubMed
  19. PLoS Genet. 2011 Mar;7(3):e1001333 - PubMed
  20. Nat Genet. 2013 Aug;45(8):918-22 - PubMed
  21. Int J Cancer. 2006 Mar 15;118(6):1481-95 - PubMed
  22. Int J Cancer. 2011 Feb 15;128(4):879-86 - PubMed
  23. Int J Cancer. 2007 Feb 15;120(4):885-91 - PubMed
  24. Nature. 2002 Oct 17;419(6908):734-8 - PubMed
  25. Science. 1999 Jul 30;285(5428):727-9 - PubMed
  26. Cancer Med. 2014 Feb;3(1):190-8 - PubMed
  27. Int J Cancer. 1998 Feb 9;75(4):546-54 - PubMed
  28. J Immunol. 2007 Mar 1;178(5):3186-97 - PubMed
  29. Br J Cancer. 2014 Aug 26;111(5):965-9 - PubMed
  30. Vaccine. 2009 Jan 29;27(5):636-9 - PubMed
  31. Clin Dev Immunol. 2012;2012:785825 - PubMed
  32. IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636 - PubMed

Publication Types